Israelis who had an infection were more protected against the Delta coronavirus variant than those who had an already highly effective COVID-19 vaccine The natural immune protection that develops after a SARS-CoV-2 infection offers considerably more of a shield against the Delta variant of the pandemic coronavirus than two doses of the Pfizer-BioNTech vaccine, according…
Category: Research Studies
One Day MD reports “Dr Richard Bartlett Inhaled Budesonide Protocol for COVID-19”
In April 2021, The Lancet reported evidence of UK’s first effective drug to treat COVID-19 in patients at home, inhaled budesonide, showing the treatment can reduce recovery time by a median of three days. The treatment has since been included in clinical guidelines for treating early-stage COVID-19 across the UK, Canada and India. Dr. Richard Bartlett shared…
Trial Site News reports “Ivermectin: Pros vs Cons. Dr. Luis Garegnani and Dr. Pierre Kory Debate The Issue”
Dr. Luis Garegnani from Argentia wrote an opinion piece on Ivermectin not having enough evidence behind it in BMJ Journals. Dr. Pierre Kory of the FLCCC disagrees. Both doctors debate this issue with Dr. Erin Stair as the moderator. About Luis Garegnani: Luis Garegnani is a Professor of Research methods and evidence-based medicine at Instituto…
Open Forum Infectious Disease reports “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection”
Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and…
Research Square reports “Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic”
Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy “Ivermectin” plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000)) in the treatment of mild/moderate and severely…
Rational Ground reports “Masks are NOT source control”
The COVID-19 conversation should have begun with minimum viable particle size under pressure, which for SARS-CoV-2-size particulates is .06 microns. This particle is under 0.3 microns, placing it firmly within the radically behaving particulate range. A single particle cluster can be composed of multiple virions and still fall well under that threshold. Furthermore, current research…
Dr. Daniels reports “mRNA Vaccine Spike Protein Problems”
In this video I discuss problems associated with the SARS-COV-2 spike protein. The mRNA vaccines deliver mRNA (instructions) that direct your cells to produce spike proteins. The spike proteins then cause your immune system to create antibodies that in turn build immunity to the SARS-COV-2 virus. That’s great’s and all, but what about the scientific…
Mercola reports “COVID Vaccines May Bring Avalanche of Neurological Disease”
The typical unprecedented vaccine takes 12 years to develop, and of all the unprecedented vaccines in development, only 2% are projected to ever make it through all Phase 2 and 3 clinical phases of testing The COVID-19 vaccine was developed with Operation Warp Speed in less than one year, which makes it virtually impossible to…
Principia Scientific International reports “COVID-19 RNA Based Vaccines And The Risk Of Prion Disease”
Vaccines have been found to cause a host of chronic, late developing adverse events. Some adverse events like type 1 diabetes may not occur until 3-4 years after a vaccine is administered [1]. In the example of type 1 diabetes the frequency of cases of adverse events may surpass the frequency of cases of severe…
MDPI reports “SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines”
The world is suffering from the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses its spike protein to enter the host cells. Vaccines that introduce the spike protein into our body to elicit virus-neutralizing antibodies are currently being developed. In this article, we note that human host…